Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Vit Georgia Parmi | Pharma | 14.0% | 48th pct | 110 |
| Med Parmasi Group | Pharma | -0.9% | 14th pct | 110 |
| Pip Company | Pharma | -15.5% | 3rd pct | 110 |
| Medimex | Pharma | — | no FY data | 110 |
| Sando Pharma | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 3 of 5 peers filed FY2024. Switch to FY2018 (5 of 5).
| Line item | Pip Company | Med Parmasi Group | Vit Georgia Parmi | Medimex | Sando Pharma |
|---|---|---|---|---|---|
| Total Current Assets | 3,360 | 637 | 664 | — | — |
| Total Non-Current Assets | 3 | 255 | 567 | — | — |
| TOTAL ASSETS | 3,363 | 892 | 1,231 | — | — |
| Total Current Liabilities | 4,920 | 210 | 152 | — | — |
| Total Non-Current Liabilities | 30 | 10 | 563 | — | — |
| TOTAL LIABILITIES | 4,950 | 221 | 715 | — | — |
| Total Equity | -1,587 | 672 | 516 | — | — |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | — | — |
| Total Debt | 0 | 28 | 528 | — | — |
| Cash & Equivalents | 3 | 21 | 6 | — | — |
| Net Debt | -3 | 7 | 523 | — | — |
Not every picked company reports every selected year — FY2024: no filing for Medimex and Sando Pharma. Those cells are left blank (no filing), not zero.